Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
697 Burke Road
Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,375.90 | 19.70 | 0.21% |
CAC 40 | 8,188.59 | 111.59 | 1.38% |
DAX 40 | 24,272.19 | 90.82 | 0.38% |
Dow JONES (US) | 46,165.12 | 88.19 | -0.19% |
FTSE 100 | 9,436.09 | 11.34 | 0.12% |
HKSE | 25,888.51 | 22.09 | -0.09% |
NASDAQ | 22,661.52 | 8.56 | -0.04% |
Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
S&P 500 | 6,658.29 | 12.77 | -0.19% |
S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
SSE Composite Index | 3,916.23 | 4.02 | 0.10% |